Review



prostate cancer epithelial cell lines pc3  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC prostate cancer epithelial cell lines pc3
    ( a ) Schematic of a preclinical treatment procedure. Two weeks after subcutaneous inoculation and in vivo uptake of <t>PC3/PSC27</t> cell recombinants, NOD/SCID mice received either single-agent or combinatorial metronomic treatment in multiple cycles. ( b ) Tumor end volume analysis. PC3 cells were inoculated alone or with PSC27 cells for subcutaneous implantation at mouse hind flanks, followed by 0.2 mg/kg mitoxantrone (MIT) and 20 mg/kg DMY treatment (single or combined). Left, comparative statistics. Right, representative tumor images. ( c ) Transcriptional analysis of typical SASP factors in stromal and cancer cells isolated via laser capture microdissection (LCM). Signals were normalized to the lowest value of placebo group. ( d ) Transcriptional analysis of two canonical senescence biomarkers p16 Ink4a and p21 Cip1 . ( e ) SA-β-Gal staining in tumor tissue at the end of therapeutic regimens. Left, representative images. Right, comparative statistics. Scale bar, 100 μm. ( f ) Apoptosis assessment via cleaved caspase 3-based immunohistochemistry staining of tumor tissues at the end of therapeutic regimen. Top, representative images. bottom, comparative statistics. Scale bar, 100 μm. ( g ) lmmunohistochemical staining of IL6 in tumor tissues at the end of therapeutic regimen. Left, representative images. Right, comparative statistics. Scale bar, 50 μm. ( i ) Circulating levels of SASP factors including AREG and IL6 in the serum of MIT/DMY-treated NOD/SCID mice. Data are presented as mean ± SD. P values were calculated using Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Prostate Cancer Epithelial Cell Lines Pc3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 15741 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prostate cancer epithelial cell lines pc3/product/ATCC
    Average 99 stars, based on 15741 article reviews
    prostate cancer epithelial cell lines pc3 - by Bioz Stars, 2026-03
    99/100 stars

    Images

    1) Product Images from "The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases"

    Article Title: The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases

    Journal: bioRxiv

    doi: 10.64898/2025.12.25.696450

    ( a ) Schematic of a preclinical treatment procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 cell recombinants, NOD/SCID mice received either single-agent or combinatorial metronomic treatment in multiple cycles. ( b ) Tumor end volume analysis. PC3 cells were inoculated alone or with PSC27 cells for subcutaneous implantation at mouse hind flanks, followed by 0.2 mg/kg mitoxantrone (MIT) and 20 mg/kg DMY treatment (single or combined). Left, comparative statistics. Right, representative tumor images. ( c ) Transcriptional analysis of typical SASP factors in stromal and cancer cells isolated via laser capture microdissection (LCM). Signals were normalized to the lowest value of placebo group. ( d ) Transcriptional analysis of two canonical senescence biomarkers p16 Ink4a and p21 Cip1 . ( e ) SA-β-Gal staining in tumor tissue at the end of therapeutic regimens. Left, representative images. Right, comparative statistics. Scale bar, 100 μm. ( f ) Apoptosis assessment via cleaved caspase 3-based immunohistochemistry staining of tumor tissues at the end of therapeutic regimen. Top, representative images. bottom, comparative statistics. Scale bar, 100 μm. ( g ) lmmunohistochemical staining of IL6 in tumor tissues at the end of therapeutic regimen. Left, representative images. Right, comparative statistics. Scale bar, 50 μm. ( i ) Circulating levels of SASP factors including AREG and IL6 in the serum of MIT/DMY-treated NOD/SCID mice. Data are presented as mean ± SD. P values were calculated using Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Figure Legend Snippet: ( a ) Schematic of a preclinical treatment procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 cell recombinants, NOD/SCID mice received either single-agent or combinatorial metronomic treatment in multiple cycles. ( b ) Tumor end volume analysis. PC3 cells were inoculated alone or with PSC27 cells for subcutaneous implantation at mouse hind flanks, followed by 0.2 mg/kg mitoxantrone (MIT) and 20 mg/kg DMY treatment (single or combined). Left, comparative statistics. Right, representative tumor images. ( c ) Transcriptional analysis of typical SASP factors in stromal and cancer cells isolated via laser capture microdissection (LCM). Signals were normalized to the lowest value of placebo group. ( d ) Transcriptional analysis of two canonical senescence biomarkers p16 Ink4a and p21 Cip1 . ( e ) SA-β-Gal staining in tumor tissue at the end of therapeutic regimens. Left, representative images. Right, comparative statistics. Scale bar, 100 μm. ( f ) Apoptosis assessment via cleaved caspase 3-based immunohistochemistry staining of tumor tissues at the end of therapeutic regimen. Top, representative images. bottom, comparative statistics. Scale bar, 100 μm. ( g ) lmmunohistochemical staining of IL6 in tumor tissues at the end of therapeutic regimen. Left, representative images. Right, comparative statistics. Scale bar, 50 μm. ( i ) Circulating levels of SASP factors including AREG and IL6 in the serum of MIT/DMY-treated NOD/SCID mice. Data are presented as mean ± SD. P values were calculated using Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Techniques Used: In Vivo, Isolation, Laser Capture Microdissection, Staining, Immunohistochemistry



    Similar Products

    prostate cancer epithelial cell lines pc3  (ATCC)
    99
    ATCC prostate cancer epithelial cell lines pc3
    ( a ) Schematic of a preclinical treatment procedure. Two weeks after subcutaneous inoculation and in vivo uptake of <t>PC3/PSC27</t> cell recombinants, NOD/SCID mice received either single-agent or combinatorial metronomic treatment in multiple cycles. ( b ) Tumor end volume analysis. PC3 cells were inoculated alone or with PSC27 cells for subcutaneous implantation at mouse hind flanks, followed by 0.2 mg/kg mitoxantrone (MIT) and 20 mg/kg DMY treatment (single or combined). Left, comparative statistics. Right, representative tumor images. ( c ) Transcriptional analysis of typical SASP factors in stromal and cancer cells isolated via laser capture microdissection (LCM). Signals were normalized to the lowest value of placebo group. ( d ) Transcriptional analysis of two canonical senescence biomarkers p16 Ink4a and p21 Cip1 . ( e ) SA-β-Gal staining in tumor tissue at the end of therapeutic regimens. Left, representative images. Right, comparative statistics. Scale bar, 100 μm. ( f ) Apoptosis assessment via cleaved caspase 3-based immunohistochemistry staining of tumor tissues at the end of therapeutic regimen. Top, representative images. bottom, comparative statistics. Scale bar, 100 μm. ( g ) lmmunohistochemical staining of IL6 in tumor tissues at the end of therapeutic regimen. Left, representative images. Right, comparative statistics. Scale bar, 50 μm. ( i ) Circulating levels of SASP factors including AREG and IL6 in the serum of MIT/DMY-treated NOD/SCID mice. Data are presented as mean ± SD. P values were calculated using Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Prostate Cancer Epithelial Cell Lines Pc3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prostate cancer epithelial cell lines pc3/product/ATCC
    Average 99 stars, based on 1 article reviews
    prostate cancer epithelial cell lines pc3 - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    ( a ) Schematic of a preclinical treatment procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 cell recombinants, NOD/SCID mice received either single-agent or combinatorial metronomic treatment in multiple cycles. ( b ) Tumor end volume analysis. PC3 cells were inoculated alone or with PSC27 cells for subcutaneous implantation at mouse hind flanks, followed by 0.2 mg/kg mitoxantrone (MIT) and 20 mg/kg DMY treatment (single or combined). Left, comparative statistics. Right, representative tumor images. ( c ) Transcriptional analysis of typical SASP factors in stromal and cancer cells isolated via laser capture microdissection (LCM). Signals were normalized to the lowest value of placebo group. ( d ) Transcriptional analysis of two canonical senescence biomarkers p16 Ink4a and p21 Cip1 . ( e ) SA-β-Gal staining in tumor tissue at the end of therapeutic regimens. Left, representative images. Right, comparative statistics. Scale bar, 100 μm. ( f ) Apoptosis assessment via cleaved caspase 3-based immunohistochemistry staining of tumor tissues at the end of therapeutic regimen. Top, representative images. bottom, comparative statistics. Scale bar, 100 μm. ( g ) lmmunohistochemical staining of IL6 in tumor tissues at the end of therapeutic regimen. Left, representative images. Right, comparative statistics. Scale bar, 50 μm. ( i ) Circulating levels of SASP factors including AREG and IL6 in the serum of MIT/DMY-treated NOD/SCID mice. Data are presented as mean ± SD. P values were calculated using Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Journal: bioRxiv

    Article Title: The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases

    doi: 10.64898/2025.12.25.696450

    Figure Lengend Snippet: ( a ) Schematic of a preclinical treatment procedure. Two weeks after subcutaneous inoculation and in vivo uptake of PC3/PSC27 cell recombinants, NOD/SCID mice received either single-agent or combinatorial metronomic treatment in multiple cycles. ( b ) Tumor end volume analysis. PC3 cells were inoculated alone or with PSC27 cells for subcutaneous implantation at mouse hind flanks, followed by 0.2 mg/kg mitoxantrone (MIT) and 20 mg/kg DMY treatment (single or combined). Left, comparative statistics. Right, representative tumor images. ( c ) Transcriptional analysis of typical SASP factors in stromal and cancer cells isolated via laser capture microdissection (LCM). Signals were normalized to the lowest value of placebo group. ( d ) Transcriptional analysis of two canonical senescence biomarkers p16 Ink4a and p21 Cip1 . ( e ) SA-β-Gal staining in tumor tissue at the end of therapeutic regimens. Left, representative images. Right, comparative statistics. Scale bar, 100 μm. ( f ) Apoptosis assessment via cleaved caspase 3-based immunohistochemistry staining of tumor tissues at the end of therapeutic regimen. Top, representative images. bottom, comparative statistics. Scale bar, 100 μm. ( g ) lmmunohistochemical staining of IL6 in tumor tissues at the end of therapeutic regimen. Left, representative images. Right, comparative statistics. Scale bar, 50 μm. ( i ) Circulating levels of SASP factors including AREG and IL6 in the serum of MIT/DMY-treated NOD/SCID mice. Data are presented as mean ± SD. P values were calculated using Student’s t -tests. ^, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Article Snippet: The prostate cancer epithelial cell lines PC3, DU145 and LNCaP were from ATCC and routinely cultured in RPMI 1640 medium supplemented with 10% FBS.

    Techniques: In Vivo, Isolation, Laser Capture Microdissection, Staining, Immunohistochemistry